<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETHCHLORVYNOL</span><br/>(eth-klor-vi'nole)<br/><span class="topboxtradename">Placidyl<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">barbiturate</span><br/><b>Prototype: </b>Secobarbital<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 500 mg, 750 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>CNS depressant effects similar to those of chloral hydrate and barbiturates. Mechanism of action not known. Also exhibits
         anticonvulsant and muscle relaxant activity. Has no analgesic properties. Effect on REM sleep not known. Not commonly used
         as a sedative because of its short duration of action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Hypnotic doses produce cerebral depression and quiet, deep sleep; sedative doses reduce anxiety and apprehension.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term therapy of simple insomnia for periods up to 1 wk.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Porphyria; patients with uncontrolled pain; first and second trimesters of pregnancy (category C). Safety during lactation
         and in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Third trimester of pregnancy; patients with mental depression or suicidal tendencies, addiction-prone individuals; impaired
         liver or kidney function; older adult or debilitated patients; patients who respond unpredictably to alcohol or barbiturates.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg b.i.d. or t.i.d.<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg1 g h.s., may give an additional 200 mg if patient awakens early<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Minimize transient giddiness and ataxia by giving drug with milk or other food. Symptoms seen in patients who apparently absorb
            the drug rapidly.
         </li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant containers (darkens on exposure to
            light; slight darkening does not affect potency).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, facial numbness, headache, mild hangover, nightmares, <span class="speceff-life">coma, respiratory failure</span>. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">GI:</span> Nausea, vomiting, aftertaste. <span class="typehead">Body as a Whole:</span> Urticaria. <span class="typehead">Musculoskeletal:</span> Muscle weakness, tremors. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="alt">Phentolamine test:</span> False-positive test results (ethchlorvynol should be withdrawn at least 24 h before the test).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> amplify CNS depression; decrease anticoagulation effect of <span class="classification">oral anticoagulants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span>  1530 min. <span class="typehead"> Peak:</span> 12 h. <span class="typehead">Duration:</span> 5 h. <span class="typehead">Distribution:</span> Localizes in adipose tissue, liver, kidney, spleen, brain, CSF, bile; crosses placenta; distribution into breast milk unknown. <span class="typehead"> Metabolism:</span> Metabolized in liver with enterohepatic cycling and possibly in kidney. <span class="typehead">Elimination:</span> 10% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 20100 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Report mental confusion, hallucinations, or drowsiness in patients receiving daytime sedation; decrease in dosage or drug
            discontinuation is indicated.
         </li>
<li>Observe intensity and duration of drug action, particularly in older adults, who may not tolerate average adult doses.</li>
<li>Do not discontinue abruptly; severe withdrawal symptoms may occur in patients taking regular doses.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Caution patient to avoid driving or engaging in other activities requiring mental alertness and physical coordination for
            at least 5 h after taking drug.
         </li>
<li>Psychological and physical dependence is possible; therefore, prolonged administration is not recommended. Urge patient to
            adhere to established drug regimen.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>